{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN7KrvUKDA","lastupdate":"2024-11-18T00:00:00.000Z","update_date":"2024-11-18T00:00:00.000Z","lastModified":"Nov 18, 2024","active":1,"confidence_score":90,"confidence_score_reason":"video or image, markets, not claimed","urlname":"rafa-laboratories","minimal_profile":null,"status":"Acquired","fullstatus":"Acquired by FIMI Opportunity Funds on Oct, 2020","acquired":1,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$R87CMHc0zHtGZgvGAW57KuJtgKVVAYqVQROY9SbYBiCcCU3nEruhxq","name":"Rafa Laboratories","oneliner":"Prescription and Over-the-Counter Medicines","registrar":"511033789","website":"https://www.rafa.co.il/en","careerspage":"https://www.rafa.co.il/careers","founded_month":1,"founded_year":1937,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/1031613","instagram":"https://www.instagram.com/explore/locations/260883023982506/rafa-laboratories-ltd"},"social":["https://www.instagram.com/explore/locations/260883023982506/rafa-laboratories-ltd","https://www.linkedin.com/company/1031613"],"flattenedsociallinks":"https://www.instagram.com/explore/locations/260883023982506/rafa-laboratories-ltd|https://www.linkedin.com/company/1031613","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"51-200","employees_exact":143,"patent":1,"raised":0,"stage":"Acquired","public_stage":"Acquired","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["rafa lab","RAFA LABORATORIES MARKETING","Rafa","Rafa labs"],"about":"Rafa Laboratories is a pharmaceutical company that markets, manufactures, and distributes consumer health products and prescription and over-the-counter medicines, mainly proprietary formulations as well as generic formulations.\n\nThe company manufactures a wide variety of medications based on in-house development and through external agreements. Rafa Laboratories is also involved in marketing drugs produced by international corporations such as Dr. Falk Pharma, Helsinn Healthcare, Boehringer Ingelheim, Purdue Pharma, 3M Healthcare, United Therapeutics, and Mundipharma.\n\nRafa Laboratories received FDA approval for their 10 mg midazolam autoinjector, which can treat seizures caused by nerve agent exposure.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97225893939","country":null,"address":{"israeli":[{"id":"db89f87d-b750-4e8d-9250-60a976d5966c","city":"Jerusalem","type":null,"address":"Shlomo Momo ha-Levi St 5, Jerusalem, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Jerusalem District","news":[{"id":"jFgZmgSahwjqx9oZGUCHj32HbyPEqurnbfsjpY23XMOuG5ifOtOFt5","date":"Jun 23, 2024","link":"https://www.themarker.com/markets/2024-06-24/ty-article/.highlight/00000190-460e-d8cb-a19d-4f4ff6850000?_atscid=7_134353_204082920_2608715_0_Txtetaxjxdshwhus8sp","source":"www.themarker.com","visible":1,"analysis":{"tags":"investment","company":"מעבדות רפא","layoffs":"not mentioned","summary":"Almost four years after acquiring a controlling stake (88%) in the pharmaceutical company Rafa Laboratories, the private equity fund FIMI is in preliminary talks to sell a 10%-15% stake to institutional investors. The accelerated growth in the field of automatic syringes for treating seizures due to exposure to biological weapons and the distribution of rare drugs in Europe allows FIMI to demand a high amount. The valuation for this sale is expected to be double the amount FIMI paid when it acquired control of Rafa at the end of 2020.","partners":"not mentioned","customers":"not mentioned","investors":"משקיעים מוסדיים","confidence":9,"key_topics":["investment","growth","valuation","sale","pharmaceuticals"],"date_of_event":"24 ביוני 2024","valuation_amount":"not mentioned","impact_on_company":"growth-positive","investment_amount":"not mentioned","structured_issues":["Investment"],"acquisition_amount":"not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HAqFWf4qDy8NxIbkd9eEMZS45LTbxBgUvpCFEPVjgsvIzCKzhHVcS7","news_summary":"שווי של 1.2 מיליארד שקל: פימי במגעים למכירת 10%–15% מרפא","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"gvRGQAmXKSfvYJ2kd9WETbppyx5KJjoKKa4oeEvTCs5HgJHuEArqeb","date":"Aug 29, 2022","link":"https://www.prnewswire.com/news-releases/rafa-receives-fda-approval-for-life-saving-midazolam-autoinjector-301614545.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Product Approval, Partnership","company":"Rafa Laboratories LTD","layoffs":"Not mentioned","summary":"Rafa Laboratories LTD has received FDA approval for its first in market 10 mg midazolam autoinjector for the treatment of status epilepticus in adults. The product was developed in partnership with the U.S. Department of Defenses (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). The autoinjector can be used to treat seizures resulting from nerve agent exposure and will replace the currently fielded convulsant antidote for nerve agent (CANA) diazepam autoinjector. The product was developed in Israel and is already sold under EUA in other territories.","partners":"U.S. Department of Defense","customers":"U.S. Department of Defense, U.S. Food and Drug Administration","investors":"FIMI Opportunity Funds","confidence":9,"key_topics":["FDA Approval","Midazolam Autoinjector","Status Epilepticus Treatment","Partnership with DOD","Emergency Medical Solutions"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Partners","Customers"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"b9a0px7NTiMrBLmINakP2yd132AwFITYrHmVjpYKvkvF640NhAX9Yg","news_summary":"Rafa Receives FDA Approval For Life-saving Midazolam Autoinjector","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9a6fcebb-db2a-40e5-9fad-8f3f2d3ac153","date":"Aug 1, 2022","link":"https://www.prnewswire.com/il/news-releases/rafa-laboratories-to-acquire-a-significant-stake-in-exceed-orphan-and-expand-its-international-capabilities-in-medicines-addressing-rare-diseases-836907883.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"strategic collaboration","company":"Rafa Laboratories LTD.","layoffs":null,"summary":"Rafa Laboratories has announced a strategic collaboration with ExCEEd Orphan for medicines addressing rare diseases in Central and Eastern Europe (CEE) and Israel. Rafa will invest an undisclosed amount in ExCEEd to strengthen its market access capabilities in the region. The collaboration aims to bring new medicines for rare diseases to both CEE and Israel. The worldwide orphan drug market is growing rapidly, and Rafas investment in ExCEEd demonstrates its commitment to becoming a leading player in this field. ExCEEd has already signed agreements with leading pharma companies, and the collaboration with Rafa will further facilitate access to medicines for rare diseases in CEE countries.","partners":"ExCEEd Orphan","customers":null,"investors":null,"confidence":9,"key_topics":["strategic collaboration","medicines for rare diseases","market access capabilities","international player","CEE and Israel"],"date_of_event":"2022-08-01","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"T7TTsOcw1QPTdjRC3wRjMWBmGgG3jiTwOvpkeuRu9cg08RBvkHnmit","news_summary":"Rafa Laboratories to acquire a significant stake in ExCEEd Orphan and expand its international capabilities in medicines addressing rare diseases","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"98a8ee98-b02e-4189-b0d6-8f638b008041","date":"Oct 28, 2020","link":"https://en.globes.co.il/en/article-fimi-buys-rafa-from-sackler-family-at-nis-700m-valuation-1001347435","source":"en.globes.co.il","visible":1,"analysis":{"tags":"acquisition","company":"Rafa Laboratories Ltd.","layoffs":null,"summary":"The Sackler family has sold its controlling stake in Rafa Laboratories Ltd. due to the fallout from the opioid scandal. FIMI Opportunity Funds has acquired a 90% stake in Rafa Laboratories at a company valuation of NIS 700 million. Rafa Laboratories is an Israeli pharmaceutical company that manufactures generic pharmaceuticals for marketing in Israel. The company has hundreds of employees and a factory in Jerusalem. The entry of FIMI as the senior partner will allow the continued operations of the factory and the promotion of Rafas business in Israeli and overseas markets.","partners":null,"customers":null,"investors":"FIMI Opportunity Funds","confidence":9,"key_topics":["Sackler family","opioid scandal","FIMI Opportunity Funds","Rafa Laboratories Ltd.","pharmaceutical company"],"date_of_event":"October 28, 2020","valuation_amount":"NIS 700 million","impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"3CSAOG3B0gfajRSRSjmKokGzwHoptsufBZ9LrYHgJRoJ5TE8Y7P8u6","news_summary":"FIMI buys Rafa from Sackler family at NIS 700m valuation","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9da09613-fba1-4e20-a197-b719f8bae405","date":"Oct 8, 2020","link":"https://en.globes.co.il/en/article-sackler-family-in-talks-to-sell-control-of-rafa-to-fimi-1001345031","source":"en.globes.co.il","visible":1,"analysis":{"tags":"pharmaceuticals, acquisition","company":"Rafa Laboratories Ltd.","layoffs":null,"summary":"The Sackler family is selling its 78% stake in Rafa Laboratories Ltd. due to its involvement in the opioid affair in the US. FIMI Opportunity Funds is in talks to acquire Rafa at a company valuation of NIS 700 million. The Sackler family owns Purdue Pharma, which filed for bankruptcy protection after the opioid scandal. Rafa is an Israeli pharmaceutical company that manufactures generic pharmaceuticals for the Israeli market. This acquisition would be one of FIMIs largest in recent years and expands its healthcare portfolio.","partners":null,"customers":null,"investors":"FIMI Opportunity Funds","confidence":9,"key_topics":["Sackler family","opioid affair","FIMI Opportunity Funds","Rafa Laboratories","acquisition"],"date_of_event":"October 8, 2020","valuation_amount":"NIS 700 million","impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"oaN7940dyaRykhfEdbdSmCnthyQIEoMfVemBqdq7w0LoRHxv6VLjgT","news_summary":"Sackler family in talks to sell control of Rafa to FIMI","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e4972cad-83e8-4290-8e84-ca57316bbd89","date":"May 1, 2019","link":"https://www.newswire.ca/news-releases/panaxia-and-rafa-sign-a-collaboration-agreement-with-plantext-to-research-and-manufacture-the-first-medical-cannabis-suppositories-intended-for-patients-suffering-from-inflammatory-bowel-disease-ibd-crohn-s-and-colitis--801999979.html","source":"www.newswire.ca","visible":1,"analysis":{"tags":"medical cannabis","company":"Panaxia Pharmaceutical Industries Israel","layoffs":null,"summary":"Panaxia Pharmaceutical Industries Israel and Rafa have signed a collaboration agreement with PlantEXT Ltd., an Israeli-Canadian medical cannabis company. They will co-develop medical cannabis products for patients suffering from Inflammatory Bowel Disease. The products will be delivered using a conventional pharmaceutical delivery system, increasing accessibility to eligible patients. The active ingredients in the cannabis suppositories are absorbed quickly and provide a speedy physical response. This collaboration aims to revolutionize the accessibility of medical cannabis in Israel.","partners":"Rafa, PlantEXT Ltd.","customers":null,"investors":null,"confidence":8,"key_topics":["collaboration agreement","medical cannabis","Inflammatory Bowel Disease","Crohns disease","Colitis"],"date_of_event":"May 1, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"dj60V8HBTzJhzr6QSlxyXVDIxZrW1fBtqLhyP2WWS5hyGFfA6WLP7q","news_summary":"Panaxia and Rafa sign a collaboration agreement with PlantEXT to research and manufacture the first medical cannabis suppositories intended for patients suffering from inflammatory bowel disease (\"IBD\", Crohn's and colitis)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"aa0d45d9-09fd-4e30-8a53-bb4b1503ae07","date":"Jul 24, 2018","link":"https://www.businesswire.com/news/home/20180724005583/en/Ology-Bioservices-RAFA-Laboratories-Announce-FDA-Approval","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"p6UiWAfceK9sH9YM0cOmsOdKH3y6jQdvu8mH9bsX4zDbt98LfEu2NR","news_summary":"Ology Bioservices and RAFA Laboratories Announce FDA Approval of the Atropine Autoinjector as a Medical Countermeasure for Chemical Nerve Agents","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"3cbb9283-6087-4572-be6d-c7be21c12ead","date":"Apr 26, 2017","link":"https://www.livescience.com/58835-drugs-needed-for-nerve-gas-exposure.html","source":"www.livescience.com","visible":1,"analysis":{"tags":["nerve gas","FDA","emergency use authorization","treatment","pharmaceutical"],"company":"Rafa Laboratories Ltd.","layoffs":null,"summary":"The U.S. government has authorized the use of a new drug injector manufactured by Rafa Laboratories Ltd., a pharmaceutical company based in Israel, to treat people exposed to nerve gas. The drug contained in the injector is atropine. However, medical experts argue that other drugs, such as pralidoxime and midazolam, are also needed for effective treatment. The FDAs emergency use authorization for the atropine injector is seen as a positive growth for Rafa Laboratories Ltd. The company is urged to focus on approving other drugs that work differently from atropine. The article highlights the importance of having a variety of drugs to treat nerve gas exposure and the need for stockpiling and preparedness in case of a chemical nerve agent threat.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["nerve gas","treatment","FDA","atropine","pralidoxime"],"date_of_event":"April 11","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"qwOErMgW8ZOfiIXtZpyYsJX7OwnvJeazoHG5UxQYNAyiXNDdsIzl6o","news_summary":"Nerve Gas Attack: New Treatment Cleared, But More Drugs Are Needed","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":8,"techcommunityinvolvement":null,"mediagallery":[],"tags":["pharma-companies","drug-design","drug-discovery","healthcare","pharmaceuticals","manufacturing","marketing","laboratories","biotechnology"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Released","products":[],"geomarkets":["Israel","Germany"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":0,"lastfunding":"Undisclosed","totalrounds":0,"fundingstage":"Acquired","totalfunding":"Undisclosed","publicinvestors":0,"lastpublicfunding":null,"totalpublicrounds":0,"totalpublicfunding":0},"team":[{"name":"Amir Levin","email":"amirl@rafa.co.il","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4LX3opgKDA","bounced":true,"claimed":0,"founder":0,"urlname":"amir-levin","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgtd2FmwsM","position":"CEO & Chairman ","last_name":"Levin","claimtoken":"nt4MI7Cztsd522GakazqHVK5yzzuSArxJgaj4chvLpl737E1vYshxG","first_name":"Amir","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/amir-levin-47138248/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-08-16 18:29:27.000000","initials":"AL","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Iddo Leshem","email":"iddo.leshem@rafa.co.il","phone":"","gender":"Male","userid":"Fz9aOVl6vGivK4wESU7esdWQHOxLrFW5Io9Zu2kAyye9KDP7fgm4Bu","bounced":false,"claimed":null,"founder":0,"urlname":"iddo-leshem","visible":1,"memberid":"Ju2jm9pO3QoiEWi7GMOnkdg69PdmHUaMtslLBkaonNYnmtdoOI3gbr","position":"CEO","last_name":"Leshem","claimtoken":"skHBOAVLGSNUWY24ucubT4dBh1EUgD0GXApZpim9yitMBuiQVn0Srr","first_name":"Iddo","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/iddoleshem/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2024-11-18 14:59:31.000000","initials":"IL","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Goozy  Hartog","email":"goozyh@rafa.co.il","phone":"","gender":"Male","userid":"55ULKuEluV6CXp1ngfjbEVv2wyj1YjZL4l0ipxaFO8yS0Cv0FKIXGL","bounced":false,"claimed":null,"founder":0,"urlname":"goozy-hartog","visible":1,"memberid":"BPTCwIFakBAaE7Uw1uRs7HW7xpNfoTrrMhYoADMfzEM9lyQHn3nSH8","position":"VP of Business Development","last_name":"Hartog","claimtoken":"3QALMIaOorOSEYRq66hwy3o4uQB9J4khH4t4GG65w2u0DcBeCg25Qf","first_name":"Goozy ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/goozy-lishay-hartog-phd-0115642a/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2024-11-18 15:01:44.000000","initials":"GH","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Liraz Levi","email":"lirazl@rafa.co.il","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4JW2v8AIDA","bounced":false,"claimed":0,"founder":0,"urlname":"liraz-levi","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg1cq2vgoM","position":"HR Director","last_name":"Levi","claimtoken":"SjRSnV0Cj1hSpY7miNZ4SKTRtuJmN6IbiHyQxlrVM6Y2Q8Ez7Yj2CN","first_name":"Liraz","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-11-18 14:59:54.000000","initials":"LL","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-04-26T00:00:00.000Z","crunchbaseid":"rafa-laboratories-ltd","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Sharon Shapira","creator_email":"shapira.sharon2@gmail.com","createdate":"2014-11-09T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCNodWCCgw","date":"Oct 2020","amount":"Undisclosed","source":"https://en.globes.co.il/en/article-fimi-buys-rafa-from-sackler-family-at-nis-700m-valuation-1001347435","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"FIMI Opportunity Funds","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNHKoJgJDA","acquiredcompany_mna_type":"Investor","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/investor_page/fimi-opportunity-funds","acquiredcompany_mna_logokey":"$T0ANpJv6HDtgD1g6FLLyS6M8R4mLHHPU5KlTHsEETCYbYGWrauwIGq","acquiredcompany_mna_urlname":"/investor_page/fimi-opportunity-funds","acquiredcompany_mna_homepage":"http://www.fimi.co.il/","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$T0ANpJv6HDtgD1g6FLLyS6M8R4mLHHPU5KlTHsEETCYbYGWrauwIGq","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"1/1937","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Rafa Laboratories","logourl":"https://storage.googleapis.com/clean-finder-353810/$R87CMHc0zHtGZgvGAW57KuJtgKVVAYqVQROY9SbYBiCcCU3nEruhxq","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$R87CMHc0zHtGZgvGAW57KuJtgKVVAYqVQROY9SbYBiCcCU3nEruhxq","seoabout":"Rafa Laboratories is a pharmaceutical company that markets, manufactures, and distributes consumer health products and prescription and over-the-counter me...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":4,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA"],"classificationsViewModel":"|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCNodWCCgw","date":"Oct 2020","amount":"Undisclosed","source":"https://en.globes.co.il/en/article-fimi-buys-rafa-from-sackler-family-at-nis-700m-valuation-1001347435","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"FIMI Opportunity Funds","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNHKoJgJDA","acquiredcompany_mna_type":"Investor","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/investor_page/fimi-opportunity-funds","acquiredcompany_mna_logokey":"$T0ANpJv6HDtgD1g6FLLyS6M8R4mLHHPU5KlTHsEETCYbYGWrauwIGq","acquiredcompany_mna_urlname":"/investor_page/fimi-opportunity-funds","acquiredcompany_mna_homepage":"http://www.fimi.co.il/","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$T0ANpJv6HDtgD1g6FLLyS6M8R4mLHHPU5KlTHsEETCYbYGWrauwIGq","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"privateequityfunding":[],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}